score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 4	version 2	0.21						Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (""transversion-high"" tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in ""transversion-low"" [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS."	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.	https://doi.org/10.1126/science.aaa1348													0				COSMIC Signature (version 2) 4 (21%)		KIRP-A4-8098		
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.QI909fs	0.7925	53.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	STAG2 p.QI909fs (Frameshift)		KIRP-A4-8098	KIRP-A4-8098-TP	KIRP-A4-8098-NB
Biologically Relevant				Copy Number	COL1A1	Amplification				0.0	0.0																					0				COL1A1 Amplification		KIRP-A4-8098	TCGA-A4-8098-01	
Biologically Relevant				Copy Number	BRIP1	Amplification				0.0	0.0																					0				BRIP1 Amplification		KIRP-A4-8098	TCGA-A4-8098-01	
Biologically Relevant				Copy Number	RAD51C	Amplification				0.0	0.0																					0				RAD51C Amplification		KIRP-A4-8098	TCGA-A4-8098-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.-1038fs (Frameshift), RNF43 Amplification, PRDM2 p.ED282del (Deletion), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: MSH3 p.-1038fs (Frameshift), RNF43 Amplification, PRDM2 p.ED282del (Deletion), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		KIRP-A4-8098		
